<?xml version="1.0" ?>
<!DOCTYPE PubmedArticleSet PUBLIC "-//NLM//DTD PubMedArticle, 1st January 2024//EN" "https://dtd.nlm.nih.gov/ncbi/pubmed/out/pubmed_240101.dtd">
<PubmedArticleSet>
<PubmedArticle><MedlineCitation Status="PubMed-not-MEDLINE" Owner="NLM"><PMID Version="1">35746502</PMID><DateRevised><Year>2022</Year><Month>07</Month><Day>16</Day></DateRevised><Article PubModel="Electronic"><Journal><ISSN IssnType="Print">2076-393X</ISSN><JournalIssue CitedMedium="Print"><Volume>10</Volume><Issue>6</Issue><PubDate><Year>2022</Year><Month>Jun</Month><Day>02</Day></PubDate></JournalIssue><Title>Vaccines</Title><ISOAbbreviation>Vaccines (Basel)</ISOAbbreviation></Journal><ArticleTitle>Immunogenicity and Safety of an Inactivated Enterovirus 71 Vaccine Administered Simultaneously with Hepatitis B Virus Vaccine, Group A Meningococcal Polysaccharide Vaccine, Measles-Rubella Combined Vaccine and Japanese Encephalitis Vaccine: A Multi-Center, Randomized, Controlled Clinical Trial in China.</ArticleTitle><ELocationID EIdType="pii" ValidYN="Y">895</ELocationID><ELocationID EIdType="doi" ValidYN="Y">10.3390/vaccines10060895</ELocationID><Abstract><AbstractText Label="BACKGROUND" NlmCategory="BACKGROUND">The aim of this study was to investigate the immunogenicity and safety of the enterovirus 71 vaccine (EV71 vaccine) administered alone or simultaneously.</AbstractText><AbstractText Label="METHODS" NlmCategory="METHODS">A multi-center, open-label, randomized controlled trial was performed involving 1080 healthy infants aged 6 months or 8 months from Shandong, Shanxi, Shaanxi, and Hunan provinces. These infants were divided into four simultaneous administration groups and EV71 vaccine separate administration group. Blood samples were collected from the infants before the first vaccination and after the completion of the vaccination. This trial was registered in the Clinical Trials Registry (NCT03519568).</AbstractText><AbstractText Label="RESULTS" NlmCategory="RESULTS">A total of 895 were included in the per-protocol analysis. The seroconversion rates of antibodies against EV71 in four simultaneous administration groups (98.44% (189/192), 94.57% (122/129), 99.47% (187/188) and 98.45% (190/193)) were non-inferior to EV71 vaccine separate administration group (97.93% [189/193]) respectively. Fever was the most common adverse event, the pairwise comparison tests showed no difference in the incidence rate of solicited, systemic or local adverse events. Three serious adverse events related to the vaccination were reported.</AbstractText><AbstractText Label="CONCLUSIONS" NlmCategory="CONCLUSIONS">The evidence of immunogenicity and safety supports that the EV71 vaccine administered simultaneously with vaccines need to be administered during the same period of time recommended in China.</AbstractText></Abstract><AuthorList CompleteYN="Y"><Author ValidYN="Y"><LastName>Liu</LastName><ForeName>Xiaodong</ForeName><Initials>X</Initials><Identifier Source="ORCID">0000-0003-2117-765X</Identifier><AffiliationInfo><Affiliation>Shandong Provincial Center for Disease Control and Prevention, Jinan 250014, China.</Affiliation></AffiliationInfo><AffiliationInfo><Affiliation>Academy of Preventive Medicine, Shandong University, Jinan 250100, China.</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><LastName>Chang</LastName><ForeName>Shaoying</ForeName><Initials>S</Initials><AffiliationInfo><Affiliation>Shanxi Provincial Center for Disease Control and Prevention, Taiyuan 030012, China.</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><LastName>Wang</LastName><ForeName>Ruize</ForeName><Initials>R</Initials><AffiliationInfo><Affiliation>Shaanxi Provincial Center for Disease Control and Prevention, Xi'an 710054, China.</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><LastName>Xiao</LastName><ForeName>Yanhui</ForeName><Initials>Y</Initials><AffiliationInfo><Affiliation>China National Biotec Group Company Limited, Beijing 100024, China.</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><LastName>Li</LastName><ForeName>Fangjun</ForeName><Initials>F</Initials><AffiliationInfo><Affiliation>Hunan Provincial Center for Disease Control and Prevention, Changsha 410005, China.</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><LastName>Xu</LastName><ForeName>Qing</ForeName><Initials>Q</Initials><AffiliationInfo><Affiliation>Shandong Provincial Center for Disease Control and Prevention, Jinan 250014, China.</Affiliation></AffiliationInfo><AffiliationInfo><Affiliation>Academy of Preventive Medicine, Shandong University, Jinan 250100, China.</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><LastName>Zhang</LastName><ForeName>Shaobai</ForeName><Initials>S</Initials><AffiliationInfo><Affiliation>Shaanxi Provincial Center for Disease Control and Prevention, Xi'an 710054, China.</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><LastName>Chen</LastName><ForeName>Xiao</ForeName><Initials>X</Initials><AffiliationInfo><Affiliation>Shanxi Provincial Center for Disease Control and Prevention, Taiyuan 030012, China.</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><LastName>Zhang</LastName><ForeName>Shangxiao</ForeName><Initials>S</Initials><AffiliationInfo><Affiliation>Hunan Provincial Center for Disease Control and Prevention, Changsha 410005, China.</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><LastName>Zhang</LastName><ForeName>Min</ForeName><Initials>M</Initials><AffiliationInfo><Affiliation>China National Biotec Group Company Limited, Beijing 100024, China.</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><LastName>Chen</LastName><ForeName>Xiaoqi</ForeName><Initials>X</Initials><AffiliationInfo><Affiliation>Wuhan Institute of Biological Products Company Limited, Wuhan 430200, China.</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><LastName>Cao</LastName><ForeName>Qingfan</ForeName><Initials>Q</Initials><AffiliationInfo><Affiliation>Rushan City Center for Disease Control and Prevention, Rushan 264500, China.</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><LastName>Liu</LastName><ForeName>Xiaoyu</ForeName><Initials>X</Initials><AffiliationInfo><Affiliation>Shaanxi Provincial Center for Disease Control and Prevention, Xi'an 710054, China.</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><LastName>Wang</LastName><ForeName>Hui</ForeName><Initials>H</Initials><AffiliationInfo><Affiliation>Shanxi Provincial Center for Disease Control and Prevention, Taiyuan 030012, China.</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><LastName>Zhan</LastName><ForeName>Daihong</ForeName><Initials>D</Initials><AffiliationInfo><Affiliation>Shimen County Center for Disease Control and Prevention, Changde 415300, China.</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><LastName>Chen</LastName><ForeName>Haiping</ForeName><Initials>H</Initials><AffiliationInfo><Affiliation>China National Biotec Group Company Limited, Beijing 100024, China.</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><LastName>Chen</LastName><ForeName>Wei</ForeName><Initials>W</Initials><AffiliationInfo><Affiliation>Wuhan Institute of Biological Products Company Limited, Wuhan 430200, China.</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><LastName>Jiang</LastName><ForeName>Jianyong</ForeName><Initials>J</Initials><AffiliationInfo><Affiliation>Haiyang City Center for Disease Control and Prevention, Haiyang 265199, China.</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><LastName>Zhang</LastName><ForeName>Chao</ForeName><Initials>C</Initials><Identifier Source="ORCID">0000-0001-6384-4516</Identifier><AffiliationInfo><Affiliation>Shaanxi Provincial Center for Disease Control and Prevention, Xi'an 710054, China.</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><LastName>Wang</LastName><ForeName>Haijiao</ForeName><Initials>H</Initials><AffiliationInfo><Affiliation>Shanxi Provincial Center for Disease Control and Prevention, Taiyuan 030012, China.</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><LastName>Gao</LastName><ForeName>Lidong</ForeName><Initials>L</Initials><AffiliationInfo><Affiliation>Hunan Provincial Center for Disease Control and Prevention, Changsha 410005, China.</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><LastName>Shi</LastName><ForeName>Xuanwen</ForeName><Initials>X</Initials><AffiliationInfo><Affiliation>China National Biotec Group Company Limited, Beijing 100024, China.</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><LastName>Yang</LastName><ForeName>Xiaoming</ForeName><Initials>X</Initials><AffiliationInfo><Affiliation>China National Biotec Group Company Limited, Beijing 100024, China.</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><LastName>Xu</LastName><ForeName>Aiqiang</ForeName><Initials>A</Initials><AffiliationInfo><Affiliation>Shandong Provincial Center for Disease Control and Prevention, Jinan 250014, China.</Affiliation></AffiliationInfo><AffiliationInfo><Affiliation>Academy of Preventive Medicine, Shandong University, Jinan 250100, China.</Affiliation></AffiliationInfo></Author></AuthorList><Language>eng</Language><DataBankList CompleteYN="Y"><DataBank><DataBankName>ClinicalTrials.gov</DataBankName><AccessionNumberList><AccessionNumber>NCT03519568</AccessionNumber></AccessionNumberList></DataBank></DataBankList><GrantList CompleteYN="Y"><Grant><GrantID>ts201511105</GrantID><Agency>the Taishan Scholar Program of Shandong Province</Agency><Country/></Grant></GrantList><PublicationTypeList><PublicationType UI="D016428">Journal Article</PublicationType></PublicationTypeList><ArticleDate DateType="Electronic"><Year>2022</Year><Month>06</Month><Day>02</Day></ArticleDate></Article><MedlineJournalInfo><Country>Switzerland</Country><MedlineTA>Vaccines (Basel)</MedlineTA><NlmUniqueID>101629355</NlmUniqueID><ISSNLinking>2076-393X</ISSNLinking></MedlineJournalInfo><KeywordList Owner="NOTNLM"><Keyword MajorTopicYN="N">foot and mouth disease</Keyword><Keyword MajorTopicYN="N">hand</Keyword><Keyword MajorTopicYN="N">inactivated enterovirus 71 vaccine</Keyword><Keyword MajorTopicYN="N">separate administration</Keyword><Keyword MajorTopicYN="N">simultaneous administration</Keyword></KeywordList><CoiStatement>Xiaoming Yang, Haiping Chen, Yanhui Xiao, Min Zhang and Xuanwen Shi are employees of the China National Biotec Group Company Limited. Xiaoqi Chen and Wei Chen are employees of the Wuhan Institute of Biological Products Co, Ltd., which developed and provided the EV71 vaccine. No other disclosures were reported.</CoiStatement></MedlineCitation><PubmedData><History><PubMedPubDate PubStatus="received"><Year>2022</Year><Month>4</Month><Day>29</Day></PubMedPubDate><PubMedPubDate PubStatus="revised"><Year>2022</Year><Month>5</Month><Day>31</Day></PubMedPubDate><PubMedPubDate PubStatus="accepted"><Year>2022</Year><Month>6</Month><Day>1</Day></PubMedPubDate><PubMedPubDate PubStatus="entrez"><Year>2022</Year><Month>6</Month><Day>24</Day><Hour>1</Hour><Minute>42</Minute></PubMedPubDate><PubMedPubDate PubStatus="pubmed"><Year>2022</Year><Month>6</Month><Day>25</Day><Hour>6</Hour><Minute>0</Minute></PubMedPubDate><PubMedPubDate PubStatus="medline"><Year>2022</Year><Month>6</Month><Day>25</Day><Hour>6</Hour><Minute>1</Minute></PubMedPubDate><PubMedPubDate PubStatus="pmc-release"><Year>2022</Year><Month>6</Month><Day>2</Day></PubMedPubDate></History><PublicationStatus>epublish</PublicationStatus><ArticleIdList><ArticleId IdType="pubmed">35746502</ArticleId><ArticleId IdType="pmc">PMC9230521</ArticleId><ArticleId IdType="doi">10.3390/vaccines10060895</ArticleId><ArticleId IdType="pii">vaccines10060895</ArticleId></ArticleIdList><ReferenceList><Reference><Citation>Robinson C.R., Doane F.W., Rhodes A.J. Report of an outbreak of febrile illness with pharyngeal lesions and exanthem: Toronto, summer 1957; Isolation of group A Coxsackie virus. Can. Med. Assoc. J. 1958;79:615&#x2013;621.</Citation><ArticleIdList><ArticleId IdType="pmc">PMC1830188</ArticleId><ArticleId IdType="pubmed">13585281</ArticleId></ArticleIdList></Reference><Reference><Citation>Hagiwara A., Tagaya I., Yoneyama T. Epidemic of hand, foot and mouth disease associated with enterovirus 71 infection. Intervirology. 1978;9:60&#x2013;63. doi: 10.1159/000148922.</Citation><ArticleIdList><ArticleId IdType="doi">10.1159/000148922</ArticleId><ArticleId IdType="pubmed">202573</ArticleId></ArticleIdList></Reference><Reference><Citation>Huang C.C., Liu C.C., Chang Y.C., Chen C.Y., Wang S.T., Yeh T.F. Neurologic complications in children with enterovirus 71 infection. N. Engl. J. Med. 1999;341:936&#x2013;942. doi: 10.1056/NEJM199909233411302.</Citation><ArticleIdList><ArticleId IdType="doi">10.1056/NEJM199909233411302</ArticleId><ArticleId IdType="pubmed">10498488</ArticleId></ArticleIdList></Reference><Reference><Citation>Wang S.M., Liu C.C., Tseng H.W., Wang J.R., Huang C.C., Chen Y.J., Yang Y.J., Lin S.J., Yeh T.F. Clinical spectrum of enterovirus 71 infection in children in southern Taiwan, with an emphasis on neurological complications. Clin. Infect. Dis. 1999;29:184&#x2013;190. doi: 10.1086/520149.</Citation><ArticleIdList><ArticleId IdType="doi">10.1086/520149</ArticleId><ArticleId IdType="pubmed">10433583</ArticleId></ArticleIdList></Reference><Reference><Citation>Yang F., Ren L., Xiong Z., Li J., Xiao Y., Zhao R., He Y., Bu G., Zhou S., Wang J., et al. Enterovirus 71 outbreak in the People&#x2019;s Republic of China in 2008. J. Clin. Microbiol. 2009;47:2351&#x2013;2352. doi: 10.1128/JCM.00563-09.</Citation><ArticleIdList><ArticleId IdType="doi">10.1128/JCM.00563-09</ArticleId><ArticleId IdType="pmc">PMC2708525</ArticleId><ArticleId IdType="pubmed">19439545</ArticleId></ArticleIdList></Reference><Reference><Citation>Wu Y., Yeo A., Phoon M.C., Tan E.L., Poh C.L., Quak S.H., Chow V.T. The largest outbreak of hand; foot and mouth disease in Singapore in 2008: The role of enterovirus 71 and coxsackievirus A strains. Int. J. Infect. Dis. 2010;14:e1076&#x2013;e1081. doi: 10.1016/j.ijid.2010.07.006.</Citation><ArticleIdList><ArticleId IdType="doi">10.1016/j.ijid.2010.07.006</ArticleId><ArticleId IdType="pubmed">20952237</ArticleId></ArticleIdList></Reference><Reference><Citation>Zhuang Z.C., Kou Z.Q., Bai Y.J., Cong X., Wang L.H., Li C., Zhao L., Yu X.J., Wang Z.Y., Wen H.L. Epidemiological Research on Hand, Foot, and Mouth Disease in Mainland China. Viruses. 2015;7:6400&#x2013;6411. doi: 10.3390/v7122947.</Citation><ArticleIdList><ArticleId IdType="doi">10.3390/v7122947</ArticleId><ArticleId IdType="pmc">PMC4690870</ArticleId><ArticleId IdType="pubmed">26690202</ArticleId></ArticleIdList></Reference><Reference><Citation>Lee B.Y., Wateska A.R., Bailey R.R., Tai J.H., Bacon K.M., Smith K.J. Forecasting the economic value of an Enterovirus 71 (EV71) vaccine. Vaccine. 2010;28:7731&#x2013;7736. doi: 10.1016/j.vaccine.2010.09.065.</Citation><ArticleIdList><ArticleId IdType="doi">10.1016/j.vaccine.2010.09.065</ArticleId><ArticleId IdType="pmc">PMC2989421</ArticleId><ArticleId IdType="pubmed">20923711</ArticleId></ArticleIdList></Reference><Reference><Citation>Zhu F.C., Meng F.Y., Li J.X., Li X.L., Mao Q.Y., Tao H., Zhang Y.T., Yao X., Chu K., Chen Q.H., et al. Efficacy, safety, and immunology of an inactivated alum-adjuvant enterovirus 71 vaccine in children in China: A multicentre, randomised, double-blind, placebo-controlled, phase 3 trial. Lancet. 2013;381:2024&#x2013;2032. doi: 10.1016/S0140-6736(13)61049-1.</Citation><ArticleIdList><ArticleId IdType="doi">10.1016/S0140-6736(13)61049-1</ArticleId><ArticleId IdType="pubmed">23726161</ArticleId></ArticleIdList></Reference><Reference><Citation>Zhu F., Xu W., Xia J., Liang Z., Liu Y., Zhang X., Tan X., Wang L., Mao Q., Wu J., et al. Efficacy, safety, and immunogenicity of an enterovirus 71 vaccine in China. N. Engl. J. Med. 2014;370:818&#x2013;828. doi: 10.1056/NEJMoa1304923.</Citation><ArticleIdList><ArticleId IdType="doi">10.1056/NEJMoa1304923</ArticleId><ArticleId IdType="pubmed">24571754</ArticleId></ArticleIdList></Reference><Reference><Citation>Wei M., Meng F., Wang S., Li J., Zhang Y., Mao Q., Hu Y., Liu P., Shi N., Tao H., et al. 2-Year Efficacy, Immunogenicity, and Safety of Vigoo Enterovirus 71 Vaccine in Healthy Chinese Children: A Randomized Open-Label Study. J. Infect. Dis. 2017;215:56&#x2013;63. doi: 10.1093/infdis/jiw502.</Citation><ArticleIdList><ArticleId IdType="doi">10.1093/infdis/jiw502</ArticleId><ArticleId IdType="pubmed">28077584</ArticleId></ArticleIdList></Reference><Reference><Citation>Hu Y., Zeng G., Chu K., Zhang J., Han W., Zhang Y., Li J., Zhu F. Five-year immunity persistence following immunization with inactivated enterovirus 71 type (EV71) vaccine in healthy children: A further observation. Hum. Vaccines Immunother. 2018;14:1517&#x2013;1523. doi: 10.1080/21645515.2018.1442997.</Citation><ArticleIdList><ArticleId IdType="doi">10.1080/21645515.2018.1442997</ArticleId><ArticleId IdType="pmc">PMC6037439</ArticleId><ArticleId IdType="pubmed">29482422</ArticleId></ArticleIdList></Reference><Reference><Citation>Guan X., Che Y., Wei S., Li S., Zhao Z., Tong Y., Wang L., Gong W., Zhang Y., Zhao Y., et al. Effectiveness and safety of an inactivated enterovirus 71 vaccine in children aged 6&#x2013;71 months in a phase IV study. Clin. Infect. Dis. 2019;71:2421&#x2013;2427. doi: 10.1093/cid/ciz1114.</Citation><ArticleIdList><ArticleId IdType="doi">10.1093/cid/ciz1114</ArticleId><ArticleId IdType="pubmed">31734699</ArticleId></ArticleIdList></Reference><Reference><Citation>Li Y.P., Liang Z.L., Xia J.L., Wu J.Y., Wang L., Song L.F., Mao Q.Y., Wen S.Q., Huang R.G., Hu Y.S., et al. Immunogenicity, safety, and immune persistence of a novel inactivated human enterovirus 71 vaccine: A phase II, Randomized, double-blind, placebo-controlled Trial. J. Infect. Dis. 2014;209:46&#x2013;55. doi: 10.1093/infdis/jit429.</Citation><ArticleIdList><ArticleId IdType="doi">10.1093/infdis/jit429</ArticleId><ArticleId IdType="pubmed">23922377</ArticleId></ArticleIdList></Reference><Reference><Citation>Head J.R., Collender P.A., Lewnard J.A., Skaff N.K., Li L., Cheng Q., Baker J.M., Li C., Chen D., Ohringer A., et al. Early evidence of inactivated enterovirus 71 vaccine impact against hand, foot, and mouth disease in a major center of ongoing transmission in China, 2011-2018: A longitudinal surveillance study. Clin. Infect. Dis. 2019;71:3088&#x2013;3095. doi: 10.1093/cid/ciz1188.</Citation><ArticleIdList><ArticleId IdType="doi">10.1093/cid/ciz1188</ArticleId><ArticleId IdType="pmc">PMC7819528</ArticleId><ArticleId IdType="pubmed">31879754</ArticleId></ArticleIdList></Reference><Reference><Citation>Zhu F.C., Liang Z.L., Li X.L., Ge H.M., Meng F.Y., Mao Q.Y., Zhang Y.T., Hu Y.M., Zhang Z.Y., Li J.X., et al. Immunogenicity and safety of an enterovirus 71 vaccine in healthy Chinese children and infants: A randomised, double-blind, placebo-controlled phase 2 clinical trial. Lancet. 2013;381:1037&#x2013;1045. doi: 10.1016/S0140-6736(12)61764-4.</Citation><ArticleIdList><ArticleId IdType="doi">10.1016/S0140-6736(12)61764-4</ArticleId><ArticleId IdType="pubmed">23352749</ArticleId></ArticleIdList></Reference><Reference><Citation>Zhang Z., Liang Z., Zeng J., Zhang J., He P., Su J., Zeng Y., Fan R., Zhao D., Ma W., et al. Immunogenicity and Safety of an Inactivated Enterovirus 71 Vaccine Administered Simultaneously With Hepatitis B Vaccine and Group A Meningococcal Polysaccharide Vaccine: A Phase 4, Open-Label, Single-Center, Randomized, Noninferiority Trial. J. Infect. Dis. 2019;220:392&#x2013;399. doi: 10.1093/infdis/jiz129.</Citation><ArticleIdList><ArticleId IdType="doi">10.1093/infdis/jiz129</ArticleId><ArticleId IdType="pubmed">30891604</ArticleId></ArticleIdList></Reference><Reference><Citation>Xu Q., Cao Q., Yang W., Liu X., Liu H., Tian X., Li J., Fang X., Jia N., Zeng G., et al. Interchangeability of two Enterovirus 71 inactivated vaccines in Chinese children: A phase IV, open-label, and randomized controlled trial. Vaccine. 2020;38:2671&#x2013;2677. doi: 10.1016/j.vaccine.2020.02.013.</Citation><ArticleIdList><ArticleId IdType="doi">10.1016/j.vaccine.2020.02.013</ArticleId><ArticleId IdType="pubmed">32067817</ArticleId></ArticleIdList></Reference><Reference><Citation>Yang B., Wu P., Wu J.T., Lau E.H., Leung G.M., Yu H., Cowling B.J. Seroprevalence of Enterovirus 71 Antibody Among Children in China: A Systematic Review and Meta-analysis. Pediatric Infect. Dis. J. 2015;34:1399&#x2013;1406. doi: 10.1097/INF.0000000000000900.</Citation><ArticleIdList><ArticleId IdType="doi">10.1097/INF.0000000000000900</ArticleId><ArticleId IdType="pmc">PMC4718881</ArticleId><ArticleId IdType="pubmed">26368058</ArticleId></ArticleIdList></Reference></ReferenceList></PubmedData></PubmedArticle></PubmedArticleSet>